Pulmonary Hypertension | Unmet Need | Pulmonary Arterial Hypertension | US/EU | 2016
Despite the recent launches of several new therapies, adding to the range of pharmacotherapies available for treating PAH, and contributing to the complexity of the PAH treatment algorithm, a number of key unmet needs remain. These include novel efficacious therapies for PAH able to prolong survival, and therapies able to significantly improve a PAH patients’ QOL.
Related Market Assessment Reports
Report
Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. Symptoms range from general malaise to serious renal and CNS manifestations…
Report
Chronic Kidney Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Kidney Disease (US)
Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. The CKD drug market primarily comprises therapies, which are…
Report
Multiple Sclerosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Multiple Sclerosis (US)
The multiple sclerosis (MS) therapy market comprises more than 20 immunomodulatory disease-modifying therapies (DMTs), and more are in the pipeline. A variety of drug classes each hold a niche…
